<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Immunology - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcimmunol/</link>
		<description>The latest articles from BMC Immunology (ISSN 1471-2172) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/39"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/38"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/37"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/36"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/35"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/34"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/33"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/32"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/31"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/9/30"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/39">
            
            <title>Comparison of human B cell activation by TLR7 and TLR9 agonists</title>
			<description>Background:
Human B cells and plasmacytoid dendritic cells (pDC) are the only cells known to express both TLR7 and TLR9.  Plasmacytoid dendritic cells are the primary IFN-alpha producing cells in response to TLR7 and TLR9 agonists.  The direct effects of TLR7 stimulation on human B cells is less understood.  The objective of this study was to compare the effects of TLR7 and TLR9 stimulation on human B cell function.  
Results:
Gene expression and protein production of cytokines, chemokines, various B cell activation markers, and immunoglobulins were evaluated.  Purified human CD19 positive B cells (99.9%, containing both naive and memory populations) from peripheral blood were stimulated with a TLR7-selective agonist (852A), TLR7/8 agonist (3M-003), or TLR9 selective agonist CpG ODN (CpG2006).  TLR7 and TLR9 agonists similarly modulated the expression of cytokine and chemokine genes (IL-6, MIP1 alpha, MIP1 beta, TNF alpha and LTA), co-stimulatory molecules (CD80, CD40 and CD58), Fc receptors (CD23, CD32), anti-apoptotic genes (BCL2L1), certain transcription factors (MYC, TCFL5), and genes critical for B cell proliferation and differentiation (CD72, IL21R).  Both agonists also induced protein expression of the above cytokines and chemokines.  Additionally, TLR7 and TLR9 agonists induced the production of IgM and IgG.  A TLR8-selective agonist was comparatively ineffective at stimulating purified human B cells.  
Conclusions:
These results demonstrate that despite their molecular differences, the TLR7 and TLR9 agonists induce similar genes and proteins in purified human B cells.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/39</link>
			
			 	<dc:creator>John A Hanten, John P Vasilakos, Christie L Riter, Lori Neys, Kenneth E Lipson, Sefik S Alkan and Woubalem Birmachu</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:39</dc:source>
			<dc:date>2008-07-24</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-39</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>39</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/38">
            
            <title>Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes</title>
			<description>Background:
The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.
Results:
We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes.  Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli.  However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 micrograms of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-gamma and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 micrograms).  
Conclusion:
Our objective was to overcome the significant obstacles currently facing DNA vaccine development.  Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost.  We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/38</link>
			
			 	<dc:creator>Rogerio S Rosada, Lucimara Gaziola de la Torre, Fabiani G Frantz, Ana PF Trombone, Carlos R Zarate-Blades, Denise M Fonseca, Patricia RM Souza, Izaira T Brandao, Ana P Masson, Edson G Soares, Simone G Ramos, Lucia H Faccioli, Celio L Silva, Maria HA Santana and Arlete AM Coelho-Castelo</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:38</dc:source>
			<dc:date>2008-07-22</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-38</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>38</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/37">
            
            <title>Regional variations in Paneth cell antimicrobial peptide expression along the mouse intestinal tract</title>
			<description>Background:
Enteric antimicrobial peptides secreted from Paneth cells, including alpha-defensins (in mice named cryptdins), are key effector molecules of innate immunity in the small intestine. The importance of Paneth cells alpha-defensins emerged from studies of enteric bacterial infection in genetically modified mice, as well as from recent studies linking reduced levels of these alpha-defensins to Cohn's disease localized to the ileum. However, analysis of expression of Paneth cell alpha-defensins is incomplete. We therefore performed a comprehensive evaluation of the distribution of antimicrobial molecules along the mouse small intestinal tract to identify potential variations in regional expression.
Results:
In conventionally reared mice, the repertoire of Paneth cell antimicrobials differs between duodenum and ileum. In contrast to the uniform expression of most Paneth cell antimicrobials, both cryptdin 4 and cryptdin-related sequences (CRS) 4C peptides were expressed at progressively increasing amounts (10exp1- and 10exp4-fold, respectively) comparing duodenum and ileum. In tissues other than the small intestine, expression of CRS peptides was noted in thymus and caecum. Most Paneth cell products were also produced in the small intestine of germ-free mice at levels similar to those in controls, however CRS4C and RegIIIgamma had reduced levels in the former (3- and 8-fold, respectively). No significant changes in expression levels of Paneth cell antimicrobial peptides was observed after oral challenge with either Salmonella enterica serovar typhimurium or Listeria monocytogenes, supporting current notions on the constitutive nature of this defensive system.
Conclusions:
The repertoire of antimicrobial peptides changes along the small intestinal tract, and a subset of these molecules are up-regulated upon colonization, but not in response to enteric bacterial pathogens. The changes detected upon colonization suggest that Paneth cell antimicrobial peptides may play an important role in commensal microbial homeostasis, in addition to their proposed role in protection against infection. In addition, the differential expression of CRS4C along the small intestine suggests mechanisms of regulation that are distinct from other Paneth cell derived antimicrobial peptides.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/37</link>
			
			 	<dc:creator>Jenny Karlsson, Katrin Putsep, Hiutung Chu, Robert J Kays, Charles L Bevins and Mats Andersson</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:37</dc:source>
			<dc:date>2008-07-17</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-37</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>37</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/36">
            
            <title>Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation</title>
			<description>Background:
Leukotriene B4 (LTB4) is a potent inflammatory mediator that also stimulates the immune response. In addition, it promotes polymorphonuclear leukocyte phagocytosis, chemotaxis, chemokinesis and modulates cytokines release. Regarding chemical instability of the leukotriene molecule, in the present study we assessed the immunomodulatory activities conferred by LTB4 released from microspheres (MS). A previous oil-in-water emulsion solvent extraction-evaporation method was chosen to prepare LTB4-loaded MS.
Results:
In the mice cremasteric microcirculation, intraescrotal injection of 0.1 ml of LTB4-loaded MS provoked significant increases in leukocyte rolling flux, adhesion and emigration besides significant decreases in the leukocyte rolling velocity. LTB4-loaded MS also increase peroxisome proliferator-activated receptor-&#945; (PPAR&#945;) expression by murine peritoneal macrophages and stimulate them to generate nitrite levels. Monocyte chemoattractant protein-1 (MCP-1) and nitric oxide (NO) productions were also increased when human umbilical vein and artery endothelial cells (HUVECs and HUAECs, respectively) were stimulated with LTB4-loaded MS.
Conclusion:
LTB4-loaded MS preserve the biological activity of the encapsulated mediator indicating their use as a new strategy to modulate cell activation, especially in the innate immune response.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/36</link>
			
			 	<dc:creator>Roberto Nicolete, Cristina Rius, Laura Piqueras, Peter J Jose, Carlos A Sorgi, Edson G Soares, Maria J Sanz and L&#250;cia H Faccioli</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:36</dc:source>
			<dc:date>2008-07-15</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-36</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>36</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/35">
            
            <title>ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages</title>
			<description>Background:
We have previously reported that ATP treatment of M bovis-BCG infected human macrophages induces P2X7 receptor-dependent killing of intracellular mycobacteria. The mechanism mediating this bactericidal effect has not been full characterized but is known to be Ca2+-dependent and to promote the maturation and acidification of mycobacteria-containing phagosomes. In this study we demonstrate that the ATP/P2X7-mediated, mycobactericidal effect also involves the induction of cell autophagy.
Results:
We report that 3 mM ATP induces rapid cell autophagy in THP1 cells and monocyte-derived macrophages within 30 minutes post-treatment, as revealed by the expression of LC3-II bands on western blot analysis. Using Ca2+-free media and selective P2X7 agonists and antagonists, ATP-induced cell autophagy was shown to be Ca2+ and P2X7 receptor-dependent. Electron microscopy of ATP-treated, BCG-infected MDMs revealed the presence of the bacteria within characteristic double-membraned autophagosomes. Confocal analysis further confirmed that pharmacological inhibition of autophagy by wortmannin or pre-treatment of macrophages with anti-P2X7 antibody blocked ATP-induced phago-lysosomal fusion. Induction of cell autophagy with ATP was also temporally associated with a fall in intracellular mycobacterial viability, which was suppressed by treatment with wortmannin or the selective P2X7 antagonist, oxidized ATP (oATP).
Conclusion:
We provide the first evidence that ATP/P2X7-mediated killing of intracellular mycobacteria involves the induction of cell autophagy. The findings support the hypothesis that autophagy plays a key role in the control of mycobacterial infections.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/35</link>
			
			 	<dc:creator>Debasis Biswas, Omar S Qureshi, Wing-Yiu Lee, Joanne E Croudace, Manuela Mura and David A Lammas</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:35</dc:source>
			<dc:date>2008-07-15</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-35</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>35</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/34">
            
            <title>CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis</title>
			<description>Background:
Wegener's Granulomatosis and Microscopic Polyangiitis are life-threatening systemic necrotizing vasculitides of unknown aetiology. The appearance of circulating antibodies to neutrophil cytoplasmic antigens (ANCA) is strongly associated with the development of the disease. A link between infection and disease has long been suspected, and the appearance of ANCA antibodies has been reported following bacterial and viral infections. The depletion of circulating B cells with monoclonal antibody therapy can induce remission, and this observation suggests a pathogenic role for B cells in this disease. As bacterial DNA is known to induce B cell proliferation and antibody production via TLR-9 stimulation, we have explored the possibility that unmethylated CpG oligodeoxynucleotide, as found in bacterial and viral DNA, may play a role in stimulating circulating autoreactive B cells to produce ANCA in patients with vasculitis.
Results:
We have confirmed that unmethylated CpG oligonucleotide is a potent stimulator of antibody production by PBMC in vitro. The stimulation of PBMC with CpG oligonucleutides resulted in the production of similar amounts of IgG in both ANCA+ patients and normal controls. In spite of this, PR3 ANCA+ patients synthesised significantly higher amount of IgG ANCA than normal controls. In MPO ANCA+ patients, there was a tendency for patients to produce higher amount of ANCA than controls, however, the difference did not reach significance. Furthermore, we were able to detect circulating MPO-reactive B cells by ELISpot assay from the peripheral blood of 2 MPO+ ANCA vasculitis patients. Together, this indicates that circulating anti-neutrophil autoreactive B cells are present in ANCA+ vasculitis patients, and they are capable of producing antibodies in response to CpG stimulation. Of note, CpG also induced the production of the relevant autoantibodies in patients with other types of autoimmune diseases.
Conclusion:
Circulating ANCA autoreactive B cells are present in patients with ANCA+ vasculitis. The production of ANCA from these cells in response to unmethylated CpG stimulation lead us to propose that stimulation of these cells by immunostimulatory DNA sequences such as CpG oligodeoxynucleotide during infection may provide a link between infection and ANCA associated vasculitis. This phenomenon may also apply to other antibody mediated autoimmune diseases.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/34</link>
			
			 	<dc:creator>Plinio R Hurtado, Lisa Jeffs, Jodie Nitschke, Mittal Patel, Ghafar Sarvestani, John Cassidy, Pravin Hissaria, David Gillis and Chen Au Peh</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:34</dc:source>
			<dc:date>2008-07-14</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-34</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>34</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/33">
            
            <title>Environmental determinants of total IgE among school children living in the rural Tropics: importance of geohelminth infections and effect of anthelmintic treatment</title>
			<description>Background:
The environmental factors that determine the elevated levels of polyclonal IgE observed in populations living in the Tropics are poorly understood but may include geohelminth infections. We investigated the association between geohelminth infections and total IgE levels in school children in rural tropical Ecuador, and assessed the effect on IgE of repeated anthelmintic treatments over a period of 12 months. The study was nested within a cluster-randomized study that randomized 68 schools to receive either 400 mg of albendazole every 2 months over a year or no treatment. We studied random samples of children completing follow-up and representing four groups stratified by the presence of geohelminth infection at baseline and treatment allocation. We measured levels of total IgE and anti-A. lumbricoides IgG (used as a measure of past and current geohelminth infectious exposure) in blood samples collected at the start of the study and after 12 months.
Results:
We observed elevated levels of total IgE (compared to standard reference values) at the start of the study in this population of school children (geometric mean, 1,004 IU/mL, range 12 to 22,608 IU/mL)) and baseline IgE levels were strongly associated with parameters of geohelminth infection but not with age, nutritional and socioeconomic status. After 12 months, levels of IgE fell significantly in the treatment (by 35.1%) and no treatment (by 10.4%) groups, respectively, but the fall was significantly greater in the treatment group. Falls in IgE were independently associated with albendazole treatment, having a baseline geohelminth infection and with high baseline levels of anti-A. lumbricoides IgG. Increases in IgE at 12 months were associated with the presence of geohelminth infections and increasing levels of anti-A. lumbricoides IgG at 12 months independent of treatment allocation.
Conclusion:
The data provide evidence that geohelminth infections are an important determinant of total IgE in school children in the rural Tropics and that periodic anthelmintic treatments over 12 months are associated with reductions in IgE. The failure of anthelmintic treatment to reduce IgE levels to that considered normal in industrialized countries may be attributed to continued exposure of children to geohelminths or to the effects of infections in early life in programming a long-lasting Th2-biassed immunity.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/33</link>
			
			 	<dc:creator>Philip J Cooper, Neal Alexander, Ana-Lucia Moncayo, Susana M Benitez, Martha E Chico, Maritza G Vaca and George E Griffin</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:33</dc:source>
			<dc:date>2008-06-27</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-33</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>33</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/32">
            
            <title>Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha</title>
			<description>Background:
Dendritic cells (DCs) play a crucial role in initiating effective cell-mediated immune responses, but are dysfunctional and anergic in breast cancer. Reversal of this dysfunction and establishment of optimal DC function is a key prerequisite for the induction of effective anti-cancer immune responses.
Results:
Peripheral blood DCs (PBDCs) and lymph node DCs (LNDCs) generated in vitro from adherent cultures of peripheral blood monocytes (PBMs) and lymph node monocytes (LNMs), respectively, using the 4 cytokine conditioned medium (CCM) (GM-CSF+IL-4+TNF-&#945;+IFN-&#945;) or 3 CCM (GM-CSF+IL-4+TNF-&#945;) demonstrated a significantly higher degree of recovery and functional capacity in a mixed lymphocyte DC reaction (MLDCR, p &lt; 0.001), expressed significantly higher levels of HLA-DR, CD86, compared with 2 CCM (GM-CSF+IL-4) or medium alone generated DCs from PBMs and LNMs (p &lt; 0.001). The PBDCs generated with 3 CCM or 4 CCM showed a significantly (p &lt; 0.001) enhanced macropinocytotic capability (dextran particles) and induced increased production and secretion of interleukin-12p40 (IL-12p40) in vitro (p &lt; 0.001), compared with PBDCs generated from monocytes using 2 CCM or medium alone. Lipopolysaccharide (LPS) stimulation of PBDCs generated with 4 CCM demonstrated enhanced secretion of IL-6 but not IL-12p70, compared with control DCs unstimulated with LPS (p &lt; 0.001).
Conclusion:
Dysfunctional and anergic PBDCs and LNDCs from patients with operable breast cancer can be optimally reversed by ex vivo culturing of precursor adherent monocytes using a 4 CCM containing IFN-&#945;. Maximal immunophenotypic recovery and functional reactivation of DCs is seen in the presence of IFN-&#945;. However, 4 CCM containing IFN-&#945; generated-PBDCs, do not produce and secrete IL-12p70 in vitro.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/32</link>
			
			 	<dc:creator>Sukchai Satthaporn, Mark M Aloysius, Richard A Robins, Chandan Verma, Suebwong Chuthapisith, Alasdair J Mckechnie, Mohamad El-Sheemy, Wichai Vassanasiri, David Valerio, David Clark, Jibril A Jibril and Oleg Eremin</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:32</dc:source>
			<dc:date>2008-06-27</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-32</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>32</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/31">
            
            <title>Molecular cloning and expression analysis of the STAT1 gene from olive flounder, Paralichthys olivaceus</title>
			<description>Background:
Signal transducer and activator of transcription 1 (STAT1) is a critical component of interferon (IFN)-alpha/beta and IFN-gamma signaling. Although seven isoforms of STAT proteins have been reported from mammals, limited information is available for the STAT genes in fish. We isolated complementary DNA with high similarity to mammalian STAT1 from the olive flounder, Paralichthys olivaceus.
Results:
A DNA fragment containing the conserved SH2 domain was amplified by RT-PCR using degenerate primers designed based on the highly conserved sequences in the SH2 domains of the zebrafish and mammalian STAT1. The complete cDNA sequence was obtained by 5' and 3' RACE. The flounder STAT1 transcript consisted of 2,909 bp that encoded a polypeptide of 749 amino acids. The overall similarity between flounder STAT1 and other STATs was very high, with the highest amino acid sequence identity to snakehead (89%). Phylogenetic analyses reveal that flounder STAT1 is in the same monophyletic group with snakehead STAT1. Quantitative real time RT-PCR and in situ hybridization revealed that STAT1 was expressed in almost all examined organs and tissues, with high expression in gill, spleen, kidney, and heart. The accumulation of STAT1 mRNA in different developmental stages, as determined by real time RT-PCR, increased with development.
Conclusion:
Recent cloning of various cytokine genes and the STAT1 gene of olive flounder here suggest that fish also use the highly specialized JAK-STAT pathway for cytokine signaling. Identification of other STAT genes will elucidate in detail the signal transduction system in this fish.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/31</link>
			
			 	<dc:creator>Eun-Mi Park, Jung-Ha Kang, Jung Soo Seo, GunDo Kim, Jongkyeong Chung and Tae-Jin Choi</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:31</dc:source>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-31</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>31</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2172/9/30">
            
            <title>Immunological hotspots analyzed by docking simulations: evidence for a general mechanism in pemphigus vulgaris pathology and transformation</title>
			<description>Background:
Pemphigus vulgaris (PV) is an acquired autoimmune blistering disorder in which greater than 80% of active patients produce autoantibodies to the desmosomal protein desmogelin 3 (Dsg3). As the disease progresses, 40&#8211;50% of patients may also develop reactivity to a second component of the desmosomal complex, desmogelin 1 (Dsg1). T cells are clearly required for the production of autoantibodies in PV. However, few T-cell specificities within Dsg3 or Dsg1 have been reported to date, and the precise role of T-cells in disease pathogenesis and evolution remains poorly understood. In particular, no studies have addressed the immunological mechanisms that underlie the observed clinical heterogeneity in pemphigus. We report here a structure-based technique for the screening of DRB1*0402-specific immunological (T-cell epitope) hotspots in both Dsg3 and Dsg1 glycoproteins.
Results:
High predictivity was obtained for DRB1*0402 (r2 = 0.90, s = 1.20 kJ/mol, q2 = 0.82, spress = 1.61 kJ/mol) predictive model, compared to experimental data. In silico mapping of the T-cell epitope repertoires in Dsg3 and Dsg1 glycoproteins revealed that the potential immunological hotspots of both target autoantigens are highly conserved, despite limited sequence identity (54% identical, 72% similar). A similar number of well-conserved (18%) high-affinity binders were predicted to exist within both Dsg3 and Dsg1, with analogous distribution of binding registers.
Conclusion:
This study provides interesting new insights into the possible mechanism for PV disease progression. Our data suggests that the potential T-cell epitope repertoires encoded in Dsg1 and Dsg3 is substantially overlapping, and it may be possible to apply a common, antigen-specific therapeutic strategy with efficacy across distinct clinical phases of disease.</description>
			<link>http://www.biomedcentral.com/1471-2172/9/30</link>
			
			 	<dc:creator>Joo Chuan Tong and Animesh A Sinha</dc:creator>
			
			<dc:source>BMC Immunology 2008, 9:30</dc:source>
			<dc:date>2008-06-19</dc:date>
			<dc:identifier>doi:10.1186/1471-2172-9-30</dc:identifier>
			
			
							
					<prism:publicationName>BMC Immunology</prism:publicationName>
					
			
							
					<prism:issn>1471-2172</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>30</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
